As of 4:00pm ET
| -0.55 / -1.00%|
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Services divisions. The Research and Development division develops medicines based on novel mode-of-action. The Service division offers target-to-drug discovery products and services to pharmaceutical and biotech companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. The company was founded by Onno van de Stolpe and Rudi Pauwels in 1999 and is headquartered in Mechelen, Belgium.
|Onno van de Stolpe||Chief Executive Officer & Executive Director|
|Bart Filius||Chief Financial Officer|
|Piet Wigerinck||Chief Scientific Officer|
|Andre Hoekema||Senior Vice President-Corporate Development|
|Elizabeth Goodwin||VP-Corporate Communications & Investor Relations|